National Cancer Survivors Day

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 7
Volume 17
Issue 7

CHICAGO-Sunday, June 1 marked the 15th annual Cancer Survivors’ Celebration and Walk, sponsored by the Robert H. Lurie Cancer Center of Northwestern University as part of National Cancer Survivors Day. More than 800 cancer survivors participated in the walk (see photograph).

CHICAGO-Sunday, June 1 marked the 15th annual Cancer Survivors’ Celebration and Walk, sponsored by the Robert H. Lurie Cancer Center of Northwestern University as part of National Cancer Survivors  Day. More than 800 cancer survivors participated in the walk (see photograph).

Articles in this issue
National Cancer Survivors Day
New Indication for Velcade in Previously Untreated Myeloma
Risk Factors for Mantle Cell Lymphoma Identified
RAS Mutations Enhance Chemotherapy in AML
Antidiabetic Agent Metformin May Boost pCRs in Breast Ca
Eisai Seeks Full FDA Approval for Ontak for CTCL
Symptom Screen Plus CA125 Detects Early Ovarian Ca
Cisplatin Linked to Cardiac Complications in Testicular Ca Patients
Updated X-ACT Study Results Presented
ThromboGenics and BioInvent Announce Alliance with Roche
Gene Signature Identifies Low-Risk Patients in MAGE-A3 Trial
p110-Beta Drives Cancer Growth When PTEN is Inhibited, Animal Study Shows
Proton beam RT not exempt from evidence-based medicine
Investigational Agents May be Effective for Resistant GIST
Coverage vs Cost-Cutting: A look Inside the Obama and McCain Healthcare Plans
Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia

Russ Conroy
November 21st 2024
Article

The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

ONCOLOGY Staff
November 21st 2024
Article

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors

Roman Fabbricatore
November 20th 2024
Article

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.

Subcutaneous Pembrolizumab/Chemo Meets Pharmacokinetic Endpoints in NSCLC

Tim Cortese
November 20th 2024
Article

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.